These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34830956)

  • 21. HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity.
    Tong F; Mao X; Zhang S; Xie H; Yan B; Wang B; Sun J; Wei L
    Cancer Lett; 2020 May; 478():34-44. PubMed ID: 32120025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes.
    Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189
    [No Abstract]   [Full Text] [Related]  

  • 23. Exosomes and cancer: from molecular mechanisms to clinical applications.
    Jafari A; Babajani A; Abdollahpour-Alitappeh M; Ahmadi N; Rezaei-Tavirani M
    Med Oncol; 2021 Mar; 38(4):45. PubMed ID: 33743101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Exosomes: potential liquid biopsy in head and neck cancer].
    Theodoraki MN; Ludwig S
    HNO; 2020 Feb; 68(2):106-110. PubMed ID: 31915880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salivary exosomes as potential biomarkers in cancer.
    Nair S; Tang KD; Kenny L; Punyadeera C
    Oral Oncol; 2018 Sep; 84():31-40. PubMed ID: 30115473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Exosomes Inhibit B Cell Proliferation and Activity.
    Schroeder JC; Puntigam L; Hofmann L; Jeske SS; Beccard IJ; Doescher J; Laban S; Hoffmann TK; Brunner C; Theodoraki MN; Schuler PJ
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery.
    Principe S; Hui AB; Bruce J; Sinha A; Liu FF; Kislinger T
    Proteomics; 2013 May; 13(10-11):1608-23. PubMed ID: 23505015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor exosomes: a double-edged sword in cancer therapy.
    Sun W; Luo JD; Jiang H; Duan DD
    Acta Pharmacol Sin; 2018 Apr; 39(4):534-541. PubMed ID: 29542685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Separation of plasma-derived exosomes into CD3
    Theodoraki MN; Hoffmann TK; Whiteside TL
    Clin Exp Immunol; 2018 Jun; 192(3):271-283. PubMed ID: 29431869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of lncRNA WWTR1-AS1 associates with tumor aggressiveness and unfavorable survival in head-neck squamous cell carcinoma.
    Li J; Li Z; Wu Y; Diao P; Zhang W; Wang Y; Yang J; Cheng J
    J Cell Biochem; 2019 Oct; 120(10):18266-18277. PubMed ID: 31172583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges.
    Kong L; Birkeland AC
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation.
    Qadir F; Aziz MA; Sari CP; Ma H; Dai H; Wang X; Raithatha D; Da Silva LGL; Hussain M; Poorkasreiy SP; Hutchison IL; Waseem A; Teh MT
    Mol Cancer; 2018 Jul; 17(1):97. PubMed ID: 30008265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence.
    Theodoraki MN; Hoffmann TK; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2018 Oct; 194(1):67-78. PubMed ID: 30229863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Significance of PD-L1
    Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
    Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor cells derived-exosomes as angiogenenic agents: possible therapeutic implications.
    Ahmadi M; Rezaie J
    J Transl Med; 2020 Jun; 18(1):249. PubMed ID: 32571337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma.
    Jin Y; Yang Y
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31324732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma.
    Wang HC; Chan LP; Cho SF
    Front Oncol; 2019; 9():1084. PubMed ID: 31681613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma.
    Wu X; Li J; Yan T; Ke X; Li X; Zhu Y; Yang J; Li Z
    Cancer Cell Int; 2021 Jul; 21(1):393. PubMed ID: 34303375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
    St John MA
    Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.